Barbell Medicine Podcast cover image

Episode #209: Obesity Medications

Barbell Medicine Podcast

00:00

Glucagon Like Peptide One

Liraglutide was initially approved for type two diabetes in 2010 because GLP one increases insulin release from the pancreas to help control blood sugar. It also acts at the level of the brain because there are GLP one receptors there, specifically in the hypothalamus. Subsequently, liraglUTide was approved by the FDA for treating obesity and it's about 5% greater than placebo with respect to weight loss outcomes.

Play episode from 33:51
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app